Roivant Sciences initiated with bullish view at Deutsche Bank, here’s why

Deutsche Bank initiated coverage of Roivant Sciences with a Buy rating and $14 price target. After the recent announcement of an offer from Roche to acquire portfolio company Telavant, Roivant’s premium has come out of the stock, the analyst tells investors in a research note. The firm thinks the shares are fundamentally undervalued on just Vtama and expected cash on hand post closing of the Telavant deal. It remains bullish on Roivant’s core portfolio and sees it as fundamentally undervalued.